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Abstract
Purpose To assess and compare postoperative prostate
volume changes following 532-nm laser vaporization (LV)
and transurethral resection of the prostate (TURP). To
investigate whether differences in volume reduction are
associated with differences in clinical outcome.
Methods In this prospective, non-randomized study, 184
consecutive patients undergoing 120 W LV (n = 98) or
TURP (n = 86) were included. Transrectal three-dimen-
sional ultrasound and planimetric volumetry of the prostate
were performed preoperatively, after catheter removal,
6 weeks, 6 and 12 months. Additionally, clinical outcome
parameters were recorded. Mann–Whitney U test and
analysis of covariance were utilized for statistical analysis.
Results Postoperatively, a significant prostate volume
reduction was detectable in both groups. However, the rela-
tive volume reduction was lower following LV (18.4 vs.
34.7 %, p \ 0.001). After 6 weeks, prostate volumes con-
tinued to decrease in both groups, yet differences between the
groups were less pronounced. Nonetheless, the relative vol-
ume reduction remained significantly lower following LV
(12 months 43.3 vs. 50.3 %, p \ 0.001). All clinical outcome
parameters improved significantly in both groups. However,
the maximum flow rate (Qmax) and prostate-specific antigen
(PSA) reduction were significantly lower following LV.
Subgroup analyses revealed significant differences only if the
initial prostate volume was [40 ml. Re-operations were
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Conclusions The modest but significantly lower volume
reduction following LV was associated with a lower PSA
reduction, a lower Qmax and more re-operations. Given the
lack of long-term results after LV, our results are helpful
for preoperative patient counseling. Patients with large
prostates and no clear indication for the laser might not
benefit from the procedure.
Keywords Benign prostatic hyperplasia  Laser
vaporization  Laser prostatectomy  Transurethral
resection of prostate  Ultrasound of the prostate
Introduction
The 532-nm laser technique has emerged as a viable sur-
gical option to treat prostatic bladder outlet obstruction
with the promise of decreasing morbidity. This is particu-
larly relevant in high-risk cardiovascular patients and in
individuals with imperative indications for anti-coagulation
or platelet inhibition medication [1].
Good functional short- to mid-term results have con-
sistently been reported for the first-generation 80 W laser
[2, 3]. However, long-term results are still lacking and high
re-treatment rates may indicate that tissue ablation was
inadequate using this laser [4]. The second-generation
120 W laser is characterized by improved tissue ablative
properties [5, 6]. A lower perioperative morbidity and a
clinical outcome comparable to TURP have been demon-
strated in multiple trials [3, 7]. However, long-term results
for the 120-W laser are also unknown [8], and higher re-
treatment rates compared to TURP have already been
reported particularly for patients with large prostates [9,
10].
The extent of tissue ablation influences the overall and
long-term effectiveness of de-obstructive operations of the
prostate, but has yet to be characterized for LV [11, 12].
Prostatic ultrasound is an appealing modality to investigate
volume changes in the prostate following LV. Conven-
tional biplane ultrasound volumetry is accurate in mea-
suring non-operated prostates [13]. However, precise
measurements of a prostate with a postoperative central
ablation cavity are not possible using this technique.
In the present investigation, planimetric volumetry fol-
lowing transrectal three-dimensional (3D) ultrasound of the
prostate was performed to compare postoperative changes
in prostate volumes after LV and TURP.
Patients and methods
This prospective, non-randomized study was performed in
a tertiary referral center. Consecutive patients undergoing
either 532-nm LV or conventional monopolar TURP of the
prostate between April 2008 and December 2011 were
evaluated for study participation. Exclusion criteria inclu-
ded known prostate cancer or use of 5-alpha-reductase
inhibitors. Choice of surgery was at the discretion of the
attending urologist who conducted the initial clinical
assessment. In general, LV was preferred in patients with
cardiovascular comorbidities, undergoing anti-coagulation
or anti-platelet therapy, or with a particular interest in LV.
Approval from local ethics committee was obtained. All
patients provided written informed consent.
Preoperatively, the patients underwent transrectal ultra-
sound of the prostate using a Pro Focus 2202 ultrasound
scanner (BK Medical, Denmark). The ultrasound probe
was coupled to a UA0513 rotational magnetic wheel mover
(BK Medical) to generate 3D images of the prostate.
Additionally, patients were asked to complete the Inter-
national Prostate Symptom Score (IPSS) questionnaire.
Uroflowmetry was performed, and post-micturition resid-
ual volume was measured. The preoperative blood work
included a prostate-specific antigen (PSA) test.
All operations were performed by experienced ([100
previous procedures) staff surgeons (LV 85 %, TURP
69 %) or by senior residents (LV 15 %, TUR 31 %) in form
of a supervised teaching operation. Laser vaporization was
performed as described previously [14] using the 120-W
GreenLight HPSTM laser (American Medical Systems,
Minnetonka, USA) and a 24F continuous flow Iglesias laser
resectoscope (Karl Storz GmbH, Tuttlingen, D). Monopolar
TURP was performed in a classical manner [15] using a
160-W ICC 350 generator (Erbe Elektromedizin GmbH,
Tu¨bingen, D) and a 26F continuous flow Iglesias resecto-
scope (Karl Storz). In general, resection was performed
until visualization of a wide-open prostatic cavity and an
unobstructed view from the verumontanum into the bladder.
At the conclusion of the procedure, a 20F irrigation catheter
was inserted and continuous saline irrigation was initiated.
The total laser energy (LV), weight of the removed tissue
(TURP) and operative time were recorded.
Uroflowmetry, residual volume measurement and 3D
ultrasound were performed following catheter removal.
Follow-up visits took place after 6 weeks, 6 months and
12 months. At each visit, 3D ultrasound, uroflowmetry,
residual volume measurements and a PSA test were per-
formed. The IPSS questionnaire was completed, and the
patients were specifically asked to report symptoms of
dysuria.
Planimetric volumetry of the prostate was performed on
the generated 3D images using BK-3D-View software (BK
Medical). For this purpose, the surface of the prostate was
manually encircled at each 2-mm section in the sagittal
plane of the prostate. The software calculated the total
prostate volume from all encircled sections. Two
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investigators (OG, BK) performed all measurements
without knowledge of the patients’ identity and treatment
allocation. A separate investigator (TH) controlled and
approved each measurement for the final analysis.
All data are presented as median and range. Statistical
analysis was performed using IBM SPSS Statistics version
20 (IBM, Armonk, USA) and SAS version 9.2 (SAS
Institute Inc, Cary, USA). The Fisher’s exact test and the
Mann–Whitney U test were used to compare nominal and
continuous variables between the treatment arms. Analysis
of covariance (ANCOVA) was utilized to compare post-
treatment volumes while accounting for variability in pre-
treatment volumes. The Wilcoxon signed rank test was
used to compare continuous variables within a treatment
arm at the different follow-up visits. All p values \0.05
were considered statistically significant.
Results
A total of 184 patients were enrolled in this study. Ninety-
eight patients (53 %) underwent LV and 86 patients (47 %)
TURP. The baseline characteristics of all patients are
presented in Table 1. The preoperative prostate volume,
maximum flow rate (Qmax), residual volume and IPSS were
not significantly different between the groups. Patients in
the LV group were significantly older, had better results in
the quality-of-life domain of the IPSS score, were more
often undergoing anti-coagulation or anti-platelet treatment
and more often were classified as ASA III. A significant
difference in the ASA score distribution was not detectable
between the groups. All patients underwent a preoperative,
initial postoperative and 6 weeks assessment. A total of
162 (88 %) and 146 (79.3 %) patients were available for
the evaluation after 6 and 12 months, respectively (Fig. 1
for details). The final attrition rate was 20.7 % (LV 20.4 %,
TURP 20.9 %).
Table 1 summarizes the intra- and perioperative results.
The operative time was significantly longer in the LV
group. In the LV group, significant differences in the
operative time between patients undergoing anti-coagula-
tion or anti-platelet treatment and no such treatment were
not detectable (data not shown). During LV, a median
energy of 250 kJ (39–636 kJ) was applied. The median
weight of the resected tissue in the TURP group was 17 g
(5–67 g). Major complications did not occur in either
group.
At the time of catheter removal, a significant reduction
in total prostate volume was detected in both groups.
However, the remaining prostate volume was significantly
higher following LV, even after accounting for preopera-
tive volume (Table 2). Accordingly, the relative volume
reduction was significantly lower in the LV group (18.4 vs.
34.7 %, p \ 0.001; Fig. 2a). After 6 weeks, the prostate
volume in the LV group continued to decrease. However,
the remaining prostate volume (Table 2) and the relative
volume reduction (Fig. 2a) remained significantly different
Table 1 Baseline characteristics (a), intra- and perioperative (b) and
postoperative parameters (c)
LV TURP p value
(a) Baseline
Number of patients 98 86
Age (years) 70 (49–86) 65 (46–84) \0.001*
Prostate volume (ml) 48.2
(21.6–170.6)
45.7
(17.5–128.5)
0.15
PSA (ng/ml) 3.98
(0.29–34.6)
3.51
(0.31–23.5)
0.28
IPSS
Symptom score 18 (2–32) 19 (3–35) 0.1
QoL domain 4 (0–6) 5 (0–6) 0.01*
Qmax (ml/s) 9.6 (2.3–21.9) 9.3 (1.0–30.9) 0.95
Residual volume (ml) 80 (0–650) 65 (0–1400) 0.25
Indwelling catheter (n) 24 (24.5 %) 16 (18.6 %) 0.37
ASA score 0.13
I 4 (4 %) 6 (7 %)
II 77 (79 %) 71 (83 %)
III 17 (17 %) 9 (10 %)
Coagulation modifiers (n) 64 (65.3 %) 4 (4.7 %) \0.001*
Acetylsalicylic acid (n) 46 (46.9 %) 4 (4.7 %)
Clopidogrel (n) 10 (10.2 %) 0 (0 %)
Coumarin (n) 22 (22.4 %) 0 (0 %)
Dual therapy (n) 14 (14.3 %) 0 (0 %)
(b) Intra- and perioperative
Operative time (min) 86 (35–180) 70 (20–165) 0.001*
Blood transfusion (n) 0 (0 %) 0 (0 %) n.a.
Duration of catheterization
(days)
2 (1–22) 3 (2–16) \0.001*
Re-catheterization (n) 15 (15.3 %) 10 (11.6 %) 0.5
Urinary retention (n) 9 (9.2 %) 9 (10.5 %)
Persistent hematuria (n) 2 (2 %) 0 (0 %)
Residual volume
[300 ml (n)
3 (3.1 %) 0 (0 %)
Stress urinary
incontinence (n)
1 (1 %) 1 (1.1 %)
(c) Postoperative
Urinary tract infection
(6 weeks; n)
9 (9.2 %) 1 (1.1 %) 0.02*
Dysuria (n)
6 Weeks 23 (23.5 %) 27 (31.3 %) 0.25
6 Months 3 (3.4 %) 2 (2.7 %) 1.0
12 Months 2 (2.6 %) 3 (4.4 %) 0.7
Urethral stricture (n) 0 (0 %) 3 (4.4 %) 0.1
Re-operation (n) 3 (3.4 %) 0 (0 %) 0.25
Data presented as median (range) or number (percent)
PSA prostate-specific antigen, IPSS International Prostate Symptom Score,
QoL quality of life, Qmax maximum flow rate, ASA score American Society of
Anesthesiology Score
* Indicates a statistically significant difference between the two groups
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between the groups. Between 6 weeks and 6 months, a
further significant decrease in volume was detected in both
groups (Wilcoxon test p \ 0.001). Between 6 and
12 months, significant changes in prostate volume were no
longer detectable in either group (Wilcoxon p = 0.16 and
0.06, respectively). The differences in the relative volume
reduction between the groups were still statistically sig-
nificant after 6 months (39.1 vs. 49.1 %) and 12 months
(43.3 vs. 50.3 %; Fig. 2a).
Subgroup analysis was performed to test the assumption
that LV might be more efficient in smaller prostates. For
this purpose, patients were dichotomized based on their
initial prostate volume. We found that significant differ-
ences in the final relative volume reduction between LV
and TURP were only detectable if the initial prostate vol-
ume was greater than 40 ml (Fig. 2b–c).
Another subgroup analysis was performed to investigate
if volume reduction after LV is lower in patients
undergoing anti-coagulation or anti-platelet treatment
compared to patients without any treatment. We were not
able to identify significant differences between the two
groups at any follow-up visit. The relative volume reduc-
tion in the group of patients undergoing treatment was even
slightly greater compared to the patients without treatment
(data not shown).
Figure 2d shows the relative reduction of the PSA value,
which was significantly lower following LV at the con-
clusion of the study (12 months). After 12 months, the
median PSA value in the LV group was 1.6 ng/ml
(0.13–14.2 ng/ml) and in the TURP group 1.0 ng/ml
(0.15–24.1 ng/ml). This difference was also statistically
significant (p \ 0.001).
Figure 2e–h illustrates the postoperative changes in
clinical parameters, which were all significantly improved
at the first postoperative assessment. Apart from a signifi-
cantly lower maximum flow rate in the LV group after
Fig. 1 Study profile
Table 2 Pre- and postoperative prostate volumes
LV TURP p (Mann–Whitney) p (ANCOVA)
Preoperative 48.2 (21.6–170.6) 45.7 (17.5–128.5) 0.15 n.a.
Postoperative 40.7 (14.9–138.6) 27.5 (11.2–90.1) \0.001* \0.001*
6 Weeks 31.7 (10.8–126.2) 24.4 (11.3–92.7) \0.001* \0.001*
6 Months 28.4 (10.1–119.1) 20.6 (10.1–87.9) \0.001* \0.001*
12 Months 30 (10–123.6) 21.0 (8–89) \0.001* \0.001*
Data presented as median (range)
* Indicates a statistically significant difference between the two groups
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6 months (16.8 vs. 21.1 ml/s, p = 0.02) and 12 months
(14.6 vs. 19.6 ml/s, p = 0.04), no significant differences
between groups were detected.
In the prostate volume subgroup analysis, significant
differences in the clinical parameters and the PSA reduc-
tion were also only detectable in the high-volume group. In
this group, improvement of the Qmax after 6 months
(p = 0.004, data not shown) and relative reduction of the
PSA at each follow-up visit (p \ 0.001, data not shown)
were less pronounced following LV.
Further postoperative results of the entire cohort are
displayed in Table 1. Re-operation was necessary in none
of the TUR patients but in three LV patients. Two patients
(initial prostate volumes 32.9 and 48.9 ml) had obstructive
apical tissue, which was resected after 4 and 6 months,
respectively. Another patient with persistent obstructive
symptoms underwent re-TURP after 3 months. This patient
had an initial prostate volume of 57.1 ml, and the absolute
and relative volume reduction after 6 weeks was 17 ml and
31 %, respectively. During re-TURP, 11.2 g were
removed.
Discussion
This first ever study using 3D ultrasound volumetry to
investigate postoperative volume changes in the prostate
revealed a lower volume reduction following 532-nm LV
compared to TURP. In the past, several minimally invasive
alternatives to TURP were abandoned due to insufficient
tissue ablation, which resulted in higher re-treatment rates
compared to the conventional technique [12, 16]. Knowl-
edge of postoperative volume changes can help to better
understand procedure-specific side effects and can give an
Fig. 2 Boxplots showing the relative postoperative changes in the
prostate volume in the two groups (a), the relative postoperative
changes in the prostate volume after LV and TURP for two subgroups
of patients with an initial prostate volume of less (b) and more than
40 ml (c), respectively; the relative postoperative changes in the
prostate-specific antigen (PSA) in the two groups (d) and the
postoperative changes in (e) the International Prostate Symptom
Score (IPSS), (f) the quality-of-life domain of the IPSS (QoL), (g) the
peak urinary flow rate (Qmax) and (h) the residual volume In both
groups, the outcome parameters improved significantly after the
operations. The only statistically significant difference between the
two groups was detectable for the peak urinary flow rate after 6 and
12 months (Asterisks). All boxplots represent the median, interquar-
tile range and ±1.5x interquartile range
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indication of the long-term effectiveness of a procedure.
Although the final 7–10 % difference in the relative vol-
ume reduction was not drastic, it was statistically signifi-
cant and associated with a lower PSA reduction, a lower
maximum flow rate and more re-operations in the LV
group. A significant difference in the IPSS/Qol, which is
often the primary end point of trials comparing the func-
tional outcome of the two procedures was not detectable in
the present investigation.
Additionally, our investigation revealed, for the first
time, that a distinct delay in the maximum reduction of the
prostate volume occurs regularly after LV. Following
catheter removal approximately 70 % of the final volume
reduction was detected in the TURP group compared to
only 45 % in the LV group. Six weeks after the operation,
this clear difference was no longer detectable. This
observation supports evidence for significant postoperative
prostatic swelling and its subsequent resolution following
LV. Swelling of the prostate has been identified after LV in
animals [17], but the extent of prostatic swelling associated
with LV in humans was, so far, unknown.
Prostate swelling might result in postoperative urinary
retention and dysuria, which were identified in the present
study and have been previously reported [18]. However,
despite the less pronounced delay in volume reduction
following TURP, the rate of postoperative dysuria and
urinary retention was not significantly lower in the TURP
group. Dysuria has been reported to be a typical side effect
of LV [18]. Our investigation shows that the rate of post-
operative dysuria seems to be comparable after TURP and
LV. However, we did not investigate the severity of dys-
uria in our study, which might be different following the
two procedures. From our personal experience, patients
with early postoperative severe dysuria are rarely, but more
often seen after LV compared to conventional TURP. The
higher rate of urinary tract infections after LV might partly
be related to a larger amount of residual necrotic tissue
after LV. Sloughing of necrotic tissue can also take part in
the delayed volume reduction after LV. In general,
improvement of postoperative volume reduction was
accompanied by an improvement of urinary symptoms, and
after 6 months, volume reduction and the clinical param-
eters remained stable in both groups.
It is not known how much tissue needs to be removed to
achieve significant symptom improvement after a de-
obstructive operation. In some investigations, a strong
correlation between the extent of tissue removal and the
short-term clinical outcome was detectable, while other
studies did not demonstrate this relationship [19–22]. In
contrast to the present investigation, earlier studies failed to
identify a significantly lower Qmax following LV [3]. Most
of these studies enrolled fewer numbers of patients than the
present study. Thus, it is possible that these studies were
underpowered to detect a difference in this endpoint.
However, it is also possible that, e.g., the higher age and
differences in bladder function of the patients undergoing
LV in the present study account for this difference.
The subgroup analysis revealed that the effectiveness of
LV decreases with an increase in the initial prostate vol-
ume. The volume reduction and the Qmax measurements
after LV were only significantly lower compared to TURP
if the prostate volume was larger than 40 ml. It is possible
that the surgeons’ familiarity with LV in larger prostates is
responsible for this difference. However, given the expe-
rience status of the surgeons and the fairly low cutoff value
of 40 ml, it is unlikely that individual size limitations are
the main reason for the worse outcome following LV in the
higher volume group. Two of the three patients who had a
re-operation following LV had a prostate volume larger
than 40 ml. It has previously been reported that the re-
operation rate for larger prostates is significantly higher
after LV compared to TURP [9, 10].
A potential explanation for the lower volume reduction
after LV are residual stromal fibers, which extend into the
resection cavity during LV and can impair the vaporization
efficiency and, probably even more important, the visual
identification of the prostatic capsule for the surgeon [23].
Laser fiber degradation associated with a decrease in power
output from the laser fiber can furthermore reduce tissue
vaporization and lead to increased tissue coagulation [24].
This effect might be more pronounced in larger prostates,
for which the subgroup analysis revealed inferior results.
Planimetric volumetry of the prostate was chosen since
it is an adequate technique to measure both preoperative
and postoperative prostate volumes. By measuring the
prostate volume and not the resection cavity, the results of
the measurement remain unaffected by the filling volume
of the bladder. Planimetric volumetry of the prostate has
been shown to have much lower variability and higher
reliability compared to conventional biplane measurements
[25]. The accuracy is greater than 95 % when a step size of
4 mm is used for the measurements [26]. A step size of
2 mm, as chosen in the present investigation, is likely to
result in an even higher accuracy.
A drawback of this study is its non-randomized design,
which resulted in a higher number of patients under
ongoing anti-coagulation or platelet inhibition in the LV
group. It is possible that surgeons are more cautious to
perform extensive tissue ablation in these patients. Thus,
the imbalance between the groups might account to some
extent for the differences in volume reduction observed
between the two groups. However, our subgroup analysis
revealed that the use of coagulation modifiers had no sig-
nificant impact on the volume reduction in the LV group.
Although our study was not powered for this subgroup
analysis, it indicates that the imbalance between the groups
1272 World J Urol (2014) 32:1267–1274
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did not generate a significant bias in our study. The mod-
erate attrition rate of 20.7 % is another potential limitation.
Patient dropout is an expected issue in this elderly patient
population. Comparable rates have been reported even in
studies that did not require repeated transrectal ultrasounds
[27, 28]. The dropout rate was similar between the two
groups, and we do not expect this to create a specific bias
toward either group given that follow-up protocols were
identical.
In conclusion, we demonstrated that differences in the
volume reduction between LV and TURP were modest but
statistically significant. The lower volume reduction after
LV affected, at least to some degree, the short-term out-
come and might affect the long-term results. The known
advantages of the laser may outweigh the consequences of
a lower volume reduction in high-risk patients. However,
patients without clear indications for LV and with large
prostates should be counseled appropriately prior to
selecting this procedure and, depending on their prostate
volume, should also be informed about alternative treat-
ment options such as holmium laser enucleation or open
surgery.
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